Oropharynx Squamous Cell CarcinomaCURVENCT04725396
Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC
A study testing Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP). and Conventional Mandibular Reconstruction (MR without PVP) in people with Oropharynx Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma, run by UNICANCER at 10 sites in France.
Trial summary
This is a national multicenter, randomized, stratified, open label study, aiming to compare mandibular reconstruction (MR) with or without preoperative virtual planning (PVP), in patients with oral/oropharyngeal cancer (OOPC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oropharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- What is being tested?
- Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP). and Conventional Mandibular Reconstruction (MR without PVP)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 132 participants
- Where
- 10 sitesFrance
- Study dates
- 20 Apr 2021to 15 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 years or over
- Primary or recurrent OOPC, histologically proven, requiring segmental mandibulectomy
- Planned immediate fibula free flap MR to be performed at the same time as the tumor ablation by segmental mandibulectomy
- MR requiring at least one osteotomy for contouring the flap (i.e. at least 2 bone fragments)
- East Cooperative Oncology Group (ECOG) performance status 0 or 1
- American Society of Anesthesiologists Physical Status (ASA) score 1, 2, or 3
Show all 10Show fewer
- Patients considered fit for surgery as decided by the multidisciplinary team
- Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures
- Patients must be affiliated to a Social Security System (or equivalent)
- Patients must have signed a written informed consent form prior to any trial specific procedures. If the patients are physically unable to give their written consent, a trusted person of their choice, not related to the investigator or the sponsor, can confirm in writing the patient's consent
Who cannot join
- Non resectable tumors (T4b primary tumor, non resectable metastatic lymph nodes)
- Comorbidities factors that would contraindicate surgery (such as severe peripheral artery disease)
- MR requiring no osteotomy for contouring the flap (i.e. one bone fragment)
- Patients with distant metastatic disease as determined by routine pre-operative staging radiological investigations e.g. CT thorax and upper abdomen or positron emission tomography (PET)-CT
- Other uncontrolled malignancy
- Serious, non-healing or dehiscing wound, active ulcer or ongoing bone fracture at the free-flap donor site
Show all 9Show fewer
- Patients unwilling or unable to comply with the medical follow-up required by the trial because of psychosocial, familial, social, or geographical reasons
- Participation in another clinical study with an investigational medicinal product during the last 30 days prior to inclusion
- Patients deprived of their liberty or under protective custody or guardianship
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
France10 sites
CHU Groupe Hospitalier Pellegrin
Bordeaux, 33076
Centre François Baclesse
Caen
Centre Oscar Lambret
Lille
CHU Gui de Chauliac
Montpellier
CHU Hotel Dieu
Nantes
Centre Antoine Lacassagne
Nice, 06 103
CHU Pontchaillou
Rennes
IUCT-O
Toulouse
CHR de Valenciennes
Valenciennes
Gustave Roussy
Villejuif
About this study
Official title: A Randomized Prospective Multicenter Study Comparing Fibula Free-flap Mandibular Reconstruction With or Without Preoperative Virtual Planning in Patients With Oral or Oropharyngeal Cancer
This is a national multicenter, randomized, stratified, open label study, aiming to compare mandibular reconstruction (MR) with or without preoperative virtual planning (PVP), in patients with oral/oropharyngeal cancer (OOPC).
Read the detailed description
PVP-assisted MR includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory: Materialise laboratory).
PVP-assisted MR includes the production of :
- surgical cutting guides required for mandibular resection and fibula free-flap conformation
- preformed plates for flap osteosynthesis
Patients will be selected after the multidisciplinary decision of oncological surgery including segmental mandibulectomy and immediate MR. Patients will be randomized in 2 groups (ratio 1:1, stratified on center and tumor N status [0-1 vs 2-3]).
- Being tested
- Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP)., Conventional Mandibular Reconstruction (MR without PVP)
- Keywords
- fibula free-flap, mandibular reconstruction, preoperative virtual planning
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).Device
PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
Conventional Mandibular Reconstruction (MR without PVP)Device
Conventional Mandibular Reconstruction
| Study group | Role | What they receive |
|---|---|---|
| Patients undergoing PVP-assisted MR | Experimental | PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized). Receives: Device: Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP). |
| Patients undergoing conventional (i.e. without PVP) MR | Active comparator | Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR. Receives: Device: Conventional Mandibular Reconstruction (MR without PVP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
General Oral Health Assessment Index (GOHAI)
Oral health-related quality of life (QoL) measured 1 year after surgery using the GOHAI in the 2 groups of patients (MR with or without PVP).
The GOHAI is an oral-disease-specific QoL measure made by the patient. The GOHAI comprises 12 items grouped into three dimensions: the functional dimension (eating, speaking, swallowing); the pain or discomfort dimension (drugs, gingival sensitivity, discomfort when chewing certain foods); and, the psychosocial dimension (concerns, relational discomfort, appearance). The response format for each item is based on a five-point Likert scale: always = 1; often = 2; sometimes = 3; seldom = 4; never = 5. A summary score (ranging from 0 to 60) is calculated for each patient with a higher score indicating better oral health. GOHAI scores close to 30 have been reported in head and neck cancer patients after oncologic surgery and pedicled or free flap reconstruction.
Measured: 1-year
Secondary outcomes (17)
Time between randomization and surgery
Mean and median time between randomization and surgery
Measured: At the time of surgery, up to 45 days after randomization
Total operative time and flap ischemia time
Mean and median total operative time and mean and median flap ischemia time
Measured: Post surgery, up to 45 days after randomization
Postoperative surgical complication rate (including free-flap failure rate)
Surgical complication rates defined as local complication requiring another intervention in the first postoperative month, including free-flap failure rates
Measured: Post surgery, up to 45 days after randomization
Delayed surgical complication rate
Delayed surgical complication rates defined as local complication occurring after the first postoperative month: non-union (pseudo-arthrosis), osteosynthesis-associated infection…
Measured: Post surgery, up to 45 days after randomization
Functional outcome: Performance Status Scales for Head and Neck (PSS-HN)
The PSS-HN is a 3-item scale designed to evaluate functional performance of H\&N cancer patients, specifically Normalcy of Diet, Eating in Public, and Understandability of Speech. Each subscale is rated based on semi-structured interview with a score of 0 to 100, with higher scores indicating better performance. The subscale scores are reported separately, and the Normalcy of Diet subscale will be the primary score of interest for this trial.
The PSS-HN can be rated by health professionals including speech \& language therapists and research nurses. The person collecting this data will remain consistent, as far as is feasible, throughout the course of the study. Scores are determined following an unstructured interview.
Measured: At baseline and at 1 year
Functional outcome: Mouth opening range/capacity
Functional outcomes assessed by mouth opening range/capacity at baseline and at 1 year.
It will be performed by using a caliper square to measure in millimeters the inter-incisor gap, assessed by the investigator.
Measured: At baseline and at 1 year
Functional outcome: MD Anderson Dysphagia Inventory (MDADI)
The MDADI is a self-administered questionnaire designed specifically for evaluating the impact of dysphagia on the QoL of patients with head and neck cancer. It surveys QoL issues relevant to swallowing via several subscales: Emotional, Functional, and Physical. A fourth measurement, the Global subscale, is a single question designed to establish quickly an overall assessment that pertains to swallowing. A score ranging from 0 to 100 is calculated for each subscale, with higher scores indicating higher levels of dysphagia.
Measured: 1 year
Functional outcome: Speech Handicap Index (SHI)
The SHI is a well-validated and widely used self-questionnaire for assessing speech problems in OOPC patients. It comprises 3 items and provides insight into the nature and severity of patients' complaints. Response categories for all but 1 item range on a 5-point scale (''never,'' ''almost never,'' ''sometimes,'' ''almost always,'' and ''always''). The questionnaire also includes an overall speech quality item, with 4 response categories (''good,'' ''reasonable,'' ''poor,'' and ''severe''). A total SHI score is calculated by summing all items (score range, 0-120), with higher scores indicating higher levels of speech related problems.
Measured: 1 year
Functional dental status
Functional dental status (>6; 4-6, <4 functional dental units; type of dental rehabilitation) of the patients
Measured: At baseline and at 1 year
Aesthetic outcome
Subjective assessment of the aesthetic outcome in the head and neck area using a visual analog scale (VAS) by the patient and the surgeon (assessed separately).
The AESTHETIC VAS is a validated, subjective measure for esthetical perception. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "very poor looking"(0) and "very nice looking" (10).
Measured: 1 year
Morphological results: mandibular angle
Morphological results measured by the differences between the preoperative and postoperative measurements on 3D-CT-scan. The mandibular angle (in degrees) measured the amplitude of the angle existing between the ramus and body of the mandible.
Measured: At 1 year
Morphological results: bi-gonial diameter
Morphological results measured by the differences between the preoperative and postoperative measurements on 3D-CT-scan. The bi-gonial diameter (in millimeter), a measure of the contracture/reduction of the arch, is intended to measure the preservation of the native mandibular arch anatomy.
Measured: At 1 year
Morphological results: position of the gnathion
Morphological results measured by the differences between the preoperative and postoperative measurements on 3D-CT-scan. The lateral deviation (in millimeter) of gnathion in relation to the midsagittal plane will determined the degree of mandibular asymmetry.
Measured: At 1 year
Pain in the head and neck area
"no pain" (0) and "worst pain" (10).
Measured: At 1 year
Evolution of patient QoL: GOHAI score
Evolution of patient QoL GOHAI score at 6 months (this score will be compared to the score measured at baseline and at 1 year).
The GOHAI is an oral-disease-specific QoL measure made by the patient. The GOHAI comprises 12 items grouped into three dimensions: the functional dimension (eating, speaking, swallowing); the pain or discomfort dimension (drugs, gingival sensitivity, discomfort when chewing certain foods); and, the psychosocial dimension (concerns, relational discomfort, appearance). The response format for each item is based on a five-point Likert scale: always = 1; often = 2; sometimes = 3; seldom = 4; never = 5. A summary score (ranging from 0 to 60) is calculated for each patient with a higher score indicating better oral health. GOHAI scores close to 30 have been reported in head and neck cancer patients after oncologic surgery and pedicled or free flap reconstruction.
Measured: At baseline, at 6 months, and at 1 year
Evolution of patient QoL: Quality of life questionnaire - Core 30 (QLQ-C30) score
Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.
The EORTC QLQ-C30 is a general self-report questionnaire designed to assess QoL in cancer patients. It consists of five functioning scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea, and vomiting), a global QoL scale, and six single questions assessing additional symptoms commonly reported by cancer patients.
As recommended by the EORTC, the scales and single-item variables of the QLQ-C30 will be linearly transformed into a score from 0 to 100. A high score for a functioning scale and for the global QOL scale represents a better level of functioning, whereas a high score for a symptom scale or a single item scale denotes a high level of symptoms or problems.
Measured: At baseline, at 6 months and at 1 year.
Evolution of patient QoL: Quality of Life Questionnaire - Head & Neck Cancer Module (QLQ-H&N35) score
The EORTC QLQ-H\&N35 is a tumor specific self-report questionnaire for head and neck cancer patients including seven symptoms scales (pain, swallowing, senses, speech, social eating, social contacts, and sexuality) and six single items (teeth problems, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill).
As recommended by the EORTC, the scales and single-item variables of the H\&N35 questionnaire will be linearly transformed into a score from 0 to 100. A high score for a functioning scale and for the global QOL scale represents a better level of functioning, whereas a high score for a symptom scale or a single item scale denotes a high level of symptoms or problems.
Measured: At baseline, at 6 months and at 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2021
- Study start20 Apr 2021
- Primary completion15 Oct 2025
- Study completion15 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oropharynx Squamous Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 132 participants (actual)
Sponsor and investigators
- Lead sponsor
- UNICANCER
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alexandre BOZEC, Principal investigator, Centre Antoine Lacassagne, Nice
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04725396
- Sponsor's protocol ID
- UC-HNG-2009
- Other IDs
- 2020-A02655-34
- Acronym
- CURVE
- Status last verified
- Nov 2025
- First submitted
- 21 Jan 2021
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Prospective Multicenter Study Comparing Fibula Free-flap Mandibular Reconstruction With or Without Preoperative Virtual Planning in Patients With Oral or Oropharyngeal Cancer
- ClinicalTrials.gov ID
- NCT04725396
- Acronym / sponsor ID
- CURVE / UC-HNG-2009
- Keywords
- fibula free-flap, mandibular reconstruction, preoperative virtual planning
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 132 participants (actual)
- Lead sponsor
- UNICANCERUniversity, hospital or other
- Study start
- 20 Apr 2021 (actual)
- Primary completion
- 15 Oct 2025 (actual)
- Study completion
- 15 Oct 2025 (actual)
- First posted
- 26 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a national multicenter, randomized, stratified, open label study, aiming to compare mandibular reconstruction (MR) with or without preoperative virtual planning (PVP), in patients with oral/oropharyngeal cancer (OOPC).
Detailed description
PVP-assisted MR includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory: Materialise laboratory).
PVP-assisted MR includes the production of :
- surgical cutting guides required for mandibular resection and fibula free-flap conformation
- preformed plates for flap osteosynthesis
Patients will be selected after the multidisciplinary decision of oncological surgery including segmental mandibulectomy and immediate MR. Patients will be randomized in 2 groups (ratio 1:1, stratified on center and tumor N status [0-1 vs 2-3]).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients undergoing PVP-assisted MR | Experimental | Device: Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized). |
| Patients undergoing conventional (i.e. without PVP) MR | Active comparator | Device: Conventional Mandibular Reconstruction (MR without PVP)Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Aged 18 years or over
- Primary or recurrent OOPC, histologically proven, requiring segmental mandibulectomy
- Planned immediate fibula free flap MR to be performed at the same time as the tumor ablation by segmental mandibulectomy
- MR requiring at least one osteotomy for contouring the flap (i.e. at least 2 bone fragments)
- East Cooperative Oncology Group (ECOG) performance status 0 or 1
Key exclusion criteria (9 listed)
- Non resectable tumors (T4b primary tumor, non resectable metastatic lymph nodes)
- Comorbidities factors that would contraindicate surgery (such as severe peripheral artery disease)
- MR requiring no osteotomy for contouring the flap (i.e. one bone fragment)
- Patients with distant metastatic disease as determined by routine pre-operative staging radiological investigations e.g. CT thorax and upper abdomen or positron emission tomography (PET)-CT
- Other uncontrolled malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory). | Device | Patients undergoing PVP-assisted MR |
| Conventional Mandibular Reconstruction (MR without PVP)Conventional Mandibular Reconstruction | Device | Patients undergoing conventional (i.e. without PVP) MR |
Primary outcome
General Oral Health Assessment Index (GOHAI)
Time frame: 1-year
Oral health-related quality of life (QoL) measured 1 year after surgery using the GOHAI in the 2 groups of patients (MR with or without PVP). The GOHAI is an oral-disease-specific QoL measure made by the patient. The GOHAI comprises 12 items grouped into three dimensions: the functional dimension (eating, speaking, swallowing); the pain or discomfort dimension (drugs, gingival sensitivity, discomfort when chewing certain foods); and, the psychosocial dimension (concerns, relational discomfort, appearance). The response format for each item is based on a five-point Likert scale: always = 1; often = 2; sometimes = 3; seldom = 4; never = 5. A summary score (ranging from 0 to 60) is calculated for each patient with a higher score indicating better oral health. GOHAI scores close to 30 have been reported in head and neck cancer patients after oncologic surgery and pedicled or free flap reconstruction.
17 secondary outcomes
Time between randomization and surgery
Time frame: At the time of surgery, up to 45 days after randomization
Total operative time and flap ischemia time
Time frame: Post surgery, up to 45 days after randomization
Postoperative surgical complication rate (including free-flap failure rate)
Time frame: Post surgery, up to 45 days after randomization
Delayed surgical complication rate
Time frame: Post surgery, up to 45 days after randomization
Functional outcome: Performance Status Scales for Head and Neck (PSS-HN)
Time frame: At baseline and at 1 year
Functional outcome: Mouth opening range/capacity
Time frame: At baseline and at 1 year
Functional outcome: MD Anderson Dysphagia Inventory (MDADI)
Time frame: 1 year
Functional outcome: Speech Handicap Index (SHI)
Time frame: 1 year
Functional dental status
Time frame: At baseline and at 1 year
Aesthetic outcome
Time frame: 1 year
Morphological results: mandibular angle
Time frame: At 1 year
Morphological results: bi-gonial diameter
Time frame: At 1 year
Morphological results: position of the gnathion
Time frame: At 1 year
Pain in the head and neck area
Time frame: At 1 year
Evolution of patient QoL: GOHAI score
Time frame: At baseline, at 6 months, and at 1 year
Evolution of patient QoL: Quality of life questionnaire - Core 30 (QLQ-C30) score
Time frame: At baseline, at 6 months and at 1 year.
Evolution of patient QoL: Quality of Life Questionnaire - Head & Neck Cancer Module (QLQ-H&N35) score
Time frame: At baseline, at 6 months and at 1 year.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Oropharynx Squamous Cell Carcinoma
RecruitingPhase 2
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Cervical Cancer, Throat Cancer
Active, not recruitingPhase 2
p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)
Squamous Cell Carcinoma of the Oropharynx
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Active, not recruitingPhase 1
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1/2
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandre BOZEC principal investigator
Centre Antoine Lacassagne, Nice
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP). and Conventional Mandibular Reconstruction (MR without PVP) in people with Oropharynx Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma, run by UNICANCER at 10 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
General Oral Health Assessment Index (GOHAI) (time frame: 1-year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.